FDA Approves Dostarlimab for MMRd/MSI-H Rectal Cancer – MSK
oncodaily - Memorial Sloan Kettering Cancer Center (MSK) , shared on X: “The FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage II or III rectal cancer […]
AI Summary: The FDA granted accelerated approval to dostarlimab for MMRd/MSI‑H locally advanced rectal cancer, allowing some patients to avoid or delay traditional multimodality therapy. Regulators cited compelling response data prompting a new, non‑surgical management pathway for select patients — a welcome option for those hoping to skip the chemo‑radiation treadmill.
Related Stories
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 5 months
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 2 months
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 2 months
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 3 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 4 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 4 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try FDA, Adolescent Health, Drug Development, Neuroscience and look for the RSS link.
StackHealth Time Machine